Moderna, the U.S. pharmaceutical company developed the vaccine from HIV/AIDS and claimed the start of clinical trials on August 19. This is mentioned in the register of trials of the US National Institute of Health.
The candidate vaccine is based on the mRNA technology, which was successfully used during the creating of Moderna vaccine against Covid-19.
The company will test two versions of its new candidate vaccine, which is officially named mRNA-1644 (the variant is known as mRNA-1644v2-Core).
It will be the first human-tested mRNA vaccine from the HIV.
"The Phase 1 trial will reportedly involve 56 healthy adults aged 18 to 50 who do not have HIV, and will test the safety of the vaccine as well as look for a basic immune response (...) There will be four groups as part of the trial – two receiving a mix of the vaccine versions, and two receiving one or the other (...) This first phase will last approximately 10 months, and they just want to make sure it's safe and that it mounts a basic immune response. If the vaccine passes this phase, they will still need to go through phase 2 and phase 3 trials to determine how well they work at preventing HIV infection in the broader population", reads the message on the website of the US National Institute of Health.